SciELO - Scientific Electronic Library Online

 
vol.23 número1Alteración de los estudios electrofisiológicos de la forma axonal aguda del síndrome de Guillain-BarréAlgunos aspectos genéticos, moleculares y clínicos del cáncer colorrectal hereditario no polipoideo índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados

Journal

Artigo

Indicadores

  • Não possue artigos citadosCitado por SciELO

Links relacionados

  • Não possue artigos similaresSimilares em SciELO

Compartilhar


Revista Cubana de Investigaciones Biomédicas

versão impressa ISSN 0864-0300versão On-line ISSN 1561-3011

Resumo

ACOSTA ACOSTA, Josué  et al. Safety study, phase I clinical trial, of the antihepatitis B hyperimmune gammaglobulin administered in one site and together with the HbasAg recombinant vaccine: preliminary results. Rev Cubana Invest Bioméd [online]. 2004, vol.23, n.1, pp.38-42. ISSN 0864-0300.

The vaccine preparation of the recombinant HbsAg vaccine with the hyperimmune antihepatitis B gammaglobulin (passive immunization of antibodies) was used and the safety (phase I of clinical trials) of gammaglobulin was evaluated on being administered in one site together with the antihepatitis B vaccine. 25 sound volunteers aged 20-50 were immunized with the vaccine preparation of hyperimmune gammaglobulin (200 UI/mL) and with antihepatitis B vaccine (20 g HbsAg/dose), which were administered in only one site and as a whole in the deltoid region in the time 0-1 month within the immunization scheme of the vaccine (0-1-3 months). No undesirable local or systemic effects were detected in any of the participants. The inocuity observed makes possible to go on with further phases of clinical studies

Palavras-chave : GAMMAGLOBULINS [immunology]; HEPATITIS B VIRUS [immunology]; HEPATITIS B/ [immunology]; HEPATITIS B [transmission]; CLINICAL TRIALS; VIRAL HEPATITIS VACCINES [therapeutic use].

        · resumo em Espanhol     · texto em Espanhol

 

Creative Commons License Todo o conteúdo deste periódico, exceto onde está identificado, está licenciado sob uma Licença Creative Commons